Product Pathways - Tyrosine Kinase / Adaptors
HER3/ErbB3 (D22C5) XP® Rabbit mAb (Biotinylated) #14800
|14800S||100 µl ( 10 western blots )||￥4,264.00||现货查询 购买询价 防伪查询|
|14800||carrier free & custom formulation / quantity||email request|
Species cross-reactivity is determined by western blot.
Applications Key: W=Western Blotting,
Species predicted to react based on 100% sequence homology: Rat,
Specificity / Sensitivity
HER3/ErbB3 (D22C5) XP® Rabbit mAb (Biotinylated) recognizes endogenous levels of total HER3/ErbB3 protein. This antibody does not cross-react with other HER family proteins.
Source / Purification
Monoclonal antibody is produced by immunizing animals with recombinant protein corresponding to the carboxy terminus of human ErbB3 protein.
This Cell Signaling Technology antibody is conjugated to biotin under optimal conditions. The biotinylated antibody is expected to exhibit the same species cross-reactivity as the unconjugated HER3/ErbB3 (D22C5) XP® Rabbit mAb #12708.
HER3/ErbB3 is a member of the ErbB receptor protein tyrosine kinase family, but it lacks tyrosine kinase activity. Tyrosine phosphorylation of ErbB3 depends on its association with other ErbB tyrosine kinases. Upon ligand binding, heterodimers form between ErbB3 and other ErbB proteins, and ErbB3 is phosphorylated on tyrosine residues by the activated ErbB kinase (1,2). There are at least 9 potential tyrosine phosphorylation sites in the carboxy-terminal tail of ErbB3. These sites serve as consensus binding sites for signal transducing proteins, including Src family members, Grb2, and the p85 subunit of PI3 kinase, which mediate ErbB downstream signaling (3). Both Tyr1222 and Tyr1289 of ErbB3 reside within a YXXM motif and participate in signaling to PI3K (4).
Investigators have found that ErbB3 is highly expressed in many cancer cells (5) and activation of the ErbB3/PI3K pathway is correlated with malignant phenotypes of adenocarcinomas (6). Research studies have demonstrated that in tumor development, ErbB3 may function as an oncogenic unit together with other ErbB members (e.g. ErbB2 requires ErbB3 to drive breast tumor cell proliferation) (7). Thus, investigators view inhibiting interaction between ErbB3 and ErbB tyrosine kinases as a novel strategy for anti-tumor therapy.
- Yarden, Y. and Sliwkowski, M.X. (2001) Nat Rev Mol Cell Biol 2, 127-37.
- Guy, P.M. et al. (1994) Proc Natl Acad Sci U S A 91, 8132-6.
- Songyang, Z. et al. (1993) Cell 72, 767-78.
- Kim, H.H. et al. (1994) J Biol Chem 269, 24747-55.
- Sithanandam, G. et al. (2003) Carcinogenesis 24, 1581-92.
- Kobayashi, M. et al. (2003) Oncogene 22, 1294-301.
- Holbro, T. et al. (2003) Proc Natl Acad Sci U S A 100, 8933-8.
Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!
For Research Use Only. Not For Use In Diagnostic Procedures.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
XP is a registered trademark of Cell Signaling Technology, Inc.
Tween is a registered trademark of ICI Americas, Inc.
Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.
用户评论 --- 共 0 条